On January 8, 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion to enhance its Antibody-Drug Conjugate (ADC) portfolio, including promising treatments like ARX517 for metastatic prostate cancer.
Hope Medicine Inc. announces successful completion of its Phase Ib "An Open-Label Study on Safety and Efficacy of HMI-115 in Androgenetic Alopecia over 24 Weeks," advancing its research milestones.
PharmaLogic Holdings Corp. has struck a deal with clinical stage innovator ARTBIO for the production of AB001, an experimental prostate cancer treatment using lead-212.
FDA Sanctions Combination Use of Merck's KEYTRUDA (pembrolizumab) with Standard Chemoradiotherapy for Treating Stage III-IVA Cervical Cancer According to FIGO 2014 Criteria.
A transcription factor is a protein that regulates the transcription of genetic information from DNA to RNA, playing a pivotal role in the regulation of gene expression.